Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook




 

Stem-cell lines neglect ethnic minorities

21 December 2009

By Dr Aarathi Prasad

Appeared in BioNews 539

A recent letter to the New England Journal of Medicine has investigated the genetic ancestry of the most commonly used and widely distributed embryonic stem cell (ES cell) lines currently used in research, and highlighted the dearth of lines that originate from non-European populations. Dr Sean J Morrison, the author of the letter, with his Michigan University and international colleagues, described how this reduced genetic diversity might be problematic for the development of cellular therapies, which is the eventual aim of human ES cell research. Their letter states that potential benefit to patients may depend partially on the diversity of the ES cell lines available for research and clinical use.

However, what their research showed was that this potentially valuable diversity is being restricted by two issues. For several sets of cell lines, the use of embryos from common gamete donors was identified (which outside of a Petri dish would be like doing research only on a single set of siblings or half siblings and then trying to apply the findings to the general population). But the wider issue was that nearly all stem cell lines currently in use are of European and Middle Eastern (most likely Israeli) origin, with the exception of just two lines that would have been derived from donors who were of East Asian ancestry.

The scientists raised concerns that all widely distributed stem cell lines lacked population diversity. Most significantly, there are no cell lines that derive from populations with recent African ancestry. Their report recommends that future efforts to create new stem cell lines for distribution should now emphasise under-represented populations. By increasing the genetic diversity of human ES cell lines available for research, scientists will be better placed to assess to what extent the ancestry of stem cell lines influences disease, whether cellular therapies being developed will be effective in people who are not of European origin, and will reduce the risk that the potential benefits of stem cell research will be limited only to patients with certain ancestries.

SOURCES & REFERENCES
AFP | 17 December 2009
 
DNA India | 17 December 2009
 
The New England Journal of Medicine | 16 December 2009
 
BusinessWeek | 16 December 2009
 
Medpage Today | 16 December 2009
 

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust
Advertise your products and services HERE - click for further details

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation